Conformal proctectomy with sphincter preservation retains acceptable defecation functions in very low rectal cancer male patients.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1478467

Weijie Chen, Xiao Zhang, Xiaoyuan Qiu, Jiaolin Zhou, Guole Lin

{"title":"Conformal proctectomy with sphincter preservation retains acceptable defecation functions in very low rectal cancer male patients.","authors":"Weijie Chen, Xiao Zhang, Xiaoyuan Qiu, Jiaolin Zhou, Guole Lin","doi":"10.3389/fonc.2024.1478467","DOIUrl":null,"url":null,"abstract":"Background: Conformal proctectomy with sphincter preservation (CPSP) is designed to preserve the rectal wall as much as possible in very low rectal cancer patients. Evaluations of anal function and quality of life outcomes are lacking.Methods: This study included male patients with very low (≤ 5 cm from the anal verge) rectal adenocarcinoma between January 1, 2020, and January 1, 2022. A LARS score questionnaire survey and EORTC-QLQ-CR38 questionnaire survey were administered.Results: A total of 21 very low rectal cancer patients were enrolled in follow-up. The average age of the patients was 56.7 years, the tumors were 1.9 ± 0.6 cm in size, and the distance from the anal verge was 4.8 ± 0.5 cm. All patients were followed up, and the mean follow-up period was 2.7 ± 0.5 years. The LARS score increased significantly from 4.1 ± 2.8 before surgery to 19.1 ± 6.0 at the 1st year after surgery (P < 0.001) and then decreased to 13.1 ± 4.2 (P < 0.001) at the 2nd year. The quality of life of patients was also lower at the 1st year after surgery (61.1 ± 9.6 vs. 74.2 ± 11.2, P < 0.001) and was restored at the 2nd year after surgery (80.6 ± 11.9 vs. 74.2 ± 11.2, P = 0.029). During standard follow-up at the outpatient department, no rectal tumor relapse was confirmed in these patients, although 2 patients were found to have suspected recurrence of local lymph node metastasis.Conclusions: These results suggest that the CPSP technique preserves acceptable defecation function and is a safe and feasible option for male patients with very low rectal cancer.Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2100052094.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1478467"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578961/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1478467","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Conformal proctectomy with sphincter preservation (CPSP) is designed to preserve the rectal wall as much as possible in very low rectal cancer patients. Evaluations of anal function and quality of life outcomes are lacking.

Methods: This study included male patients with very low (≤ 5 cm from the anal verge) rectal adenocarcinoma between January 1, 2020, and January 1, 2022. A LARS score questionnaire survey and EORTC-QLQ-CR38 questionnaire survey were administered.

Results: A total of 21 very low rectal cancer patients were enrolled in follow-up. The average age of the patients was 56.7 years, the tumors were 1.9 ± 0.6 cm in size, and the distance from the anal verge was 4.8 ± 0.5 cm. All patients were followed up, and the mean follow-up period was 2.7 ± 0.5 years. The LARS score increased significantly from 4.1 ± 2.8 before surgery to 19.1 ± 6.0 at the 1^st year after surgery (P < 0.001) and then decreased to 13.1 ± 4.2 (P < 0.001) at the 2^nd year. The quality of life of patients was also lower at the 1^st year after surgery (61.1 ± 9.6 vs. 74.2 ± 11.2, P < 0.001) and was restored at the 2^nd year after surgery (80.6 ± 11.9 vs. 74.2 ± 11.2, P = 0.029). During standard follow-up at the outpatient department, no rectal tumor relapse was confirmed in these patients, although 2 patients were found to have suspected recurrence of local lymph node metastasis.

Conclusions: These results suggest that the CPSP technique preserves acceptable defecation function and is a safe and feasible option for male patients with very low rectal cancer.

Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2100052094.

查看原文本刊更多论文

保留括约肌的肛门成形术可为极低位直肠癌男性患者保留可接受的排便功能。

背景：保留括约肌的肛门直肠切除术（CPSP）旨在尽可能保留极低直肠癌患者的直肠壁。目前还缺乏对肛门功能和生活质量的评估：本研究纳入了 2020 年 1 月 1 日至 2022 年 1 月 1 日期间罹患超低位（距肛缘 ≤ 5 厘米）直肠腺癌的男性患者。进行了 LARS 评分问卷调查和 EORTC-QLQ-CR38 问卷调查：结果：共有 21 名极低位直肠癌患者接受了随访。患者平均年龄为 56.7 岁，肿瘤大小为 1.9 ± 0.6 厘米，距肛门边缘的距离为 4.8 ± 0.5 厘米。所有患者均接受了随访，平均随访时间为（2.7 ± 0.5）年。LARS 评分从术前的 4.1 ± 2.8 显著上升至术后第一年的 19.1 ± 6.0（P < 0.001），然后下降至术后第二年的 13.1 ± 4.2（P < 0.001）。患者的生活质量在术后第一年也较低（61.1 ± 9.6 vs. 74.2 ± 11.2，P < 0.001），在术后第二年有所恢复（80.6 ± 11.9 vs. 74.2 ± 11.2，P = 0.029）。在门诊部的标准随访中，尽管发现有2名患者疑似局部淋巴结转移复发，但这些患者均未证实直肠肿瘤复发：这些结果表明，CPSP技术保留了可接受的排便功能，是男性极低位直肠癌患者安全可行的选择。临床试验注册：https://www.chictr.org.cn/，标识符为ChiCTR2100052094。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.